ANTIFUNGAL UTILIZATION AND OUTCOME EVALUATION IN A TERTIARY HOSPITAL

Authors

  • Farida Islahudin
  • Lee Ann Yip

Abstract

ABSTRACT
Objective: The risk of fungal infection is one of the many concerns of patients admitted for chronic illness. The increase in fungal infection causes
excessive morbidity and mortality. Despite the use of antifungals, the outcome of patients remains challenging. The study was performed to identify
factors affecting the outcome of antifungal use.
Methods: A retrospective study was carried out in a local tertiary hospital for the past 1 year. Patients prescribed antifungals were included.
Results: A total of 145 patients who had been prescribed with antifungal agents within the past year were included in the study. It was noted that
patients infected with fungi were mostly elderly patients (n=83, 57.2%). A majority of the patients (n=67, 46.2%, p<0.001) were diagnosed with or
suspected to have systemic fungal infection compared to urinary fungal infection (n=31, 21.4%), oral fungal infection (n=20, 13.8%), pulmonary
fungal infection (n=19, 13.1%), and others (n=8, 5.5%). As such, intravenous antifungal was the most commonly prescribed dosage form (n=88,
60.7%, p<0.001). The mortality rate of patients with fungal infection was 35.9% (n=52). No significant factors were observed to affect the clinical
outcome of patients. However, factors affecting survival outcome in patients treated for fungal infection were targeted treatment (p=0.036), less
number of medications (p<0.001), and a higher number of antifungals prescribed (p=0.010).
Conclusion: A more comprehensive review of medication is required to ensure appropriate treatment is given to patients with fungal infection.
Keywords: Antifungal, Fungal infection, Outcome.

Downloads

Download data is not yet available.

References

REFERENCES

Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: A

review of epidemiology and management options. J Med Microbiol

;55:809-18.

Bajwa S, Kulshrestha A. Fungal infections in intensive care unit:

Challenges in diagnosis and management. Ann Med Health Sci Res

;3(2):238-44.

Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens:

Current epidemiological trends. Clin Infect Dis 2006;43:S3-14.

Vazquez JA. Invasive fungal infections in the intensive care unit. Semin

Respir Crit Care Med 2010;31(1):79-86.

Playford EG, Lipman J, Sorrell TC. Management of invasive candidiasis

in the intensive care unit. Drugs 2010;70(7):823-39.

Kanafani ZA, Perfect JR. Antimicrobial resistance: Resistance to

antifungal agents: Mechanisms and clinical impact. Clin Infect Dis

;46(1):120-8.

Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of

empirical antifungal therapy and effect on outcome among patients

with invasive Candida species infections. J Antimicrob Chemother

;60(3):613-8.

Population Distribution and Basic Demographic Characteristics.

Department of Statistics Malaysia; 2010.

Ohta K, Kosaka SN, Nakao Y, Kumura T, Hagihara K, Sakamoto E, et al.

Efficacy and safety of intravenous itraconazole as empirical antifungal

therapy for persistent fever in neutropenic patients with hematological

malignancies in Japan. Jpn Soc Hematol 2009;89:649-55.

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA,

et al. Clinical practice guideline for the use of antimicrobial agents

in neutropenic patients with cancer: 2010 Update by the Infectious

Diseases Society of America. Clin Infect Dis 2011;52(4):427-31.

Olaechea PM, Ulibarrena MA, Alvarez-Lerma F, Insausti J, Palomar M,

De la Cal MA; ENVIN-UCI Study Group. Factors related to hospital

stay among patients with nosocomial infection acquired in the intensive

care unit. Infect Control Hosp Epidemiol 2003;24(3):207-13.

Peiro S, Gomez G, Rejas J, Guadarrama I, Blanca AB. Length of stay

and antifungal treatments costs in patients with systemic mycosis:

Description and associated factors. Value Health 2002;5(6):564.

Baddley JW, Stephens JM, Ji X, Gao X, Schlamm HT, Tarallo M.

Aspergillosis in Intensive Care Unit (ICU) patients: Epidemiology and

economic outcomes. BMC Infect Dis 2013;13:29.

Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS,

et al. Time to initiation of fluconazole therapy impacts mortality in

patients with candidemia: A multi-institutional study. Clin Infect Dis

;43(1):25-31.

Karthaus M, Doellmann T, Klimasch T, Elser C, Rosenthal C, Ganser A,

et al. Intensive intravenous amphotericin B for prophylaxis of systemic

fungal infections. Results of a prospective controlled pilot study in

acute leukemia patients. Chemotherapy 2000;46(4):293-302.

Neely MN, Ghannoum MA. The exciting future of antifungal therapy.

Eur J Clin Microbiol Infect Dis 2000;19(12):897-914.

Ishida K, Ishida H, Narita M, Sairenchi T, Saito Y, Fukutomi H, et al.

Factors affecting renal function in 119 985 adults over three years. QJM

;94(10):541-50.

Jang ES, Jeong SH, Hwang SH, Kim HY, Ahn SY, Lee J, et al. Effects of

coffee, smoking, and alcohol on liver function tests: A comprehensive

cross-sectional study. BMC Gastroenterol 2012;12:145.

Cortés JA, Reyes P, Gómez CH, Cuervo SI, Rivas P, Casas CA,

et al. Clinical and epidemiological characteristics and risk factors

for mortality in patients with candidemia in hospitals from Bogotá,

Colombia. Braz J Infect Dis 2014;18(6):631-7.

Hahn-Ast C, Glasmacher A, Mückter S, Schmitz A, Kraemer A,

Marklein G, et al. Overall survival and fungal infection-related

mortality in patients with invasive fungal infection and neutropenia

after myelosuppressive chemotherapy in a tertiary care centre from

to 2006. J Antimicrob Chemother 2010;65(4):761-8.

Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients.

Am J Geriatr Pharmacother 2007;5(4):345-51.

Kontoyiannis DP. Invasive mycoses: Strategies for effective

management. Am J Med 2012;125 1 Suppl: S25-38.

Kourkoumpetis TK, Velmahos GC, Ziakas PD, Tampakakis E,

Manolakaki D, Coleman JJ, et al. The effect of cumulative length of

hospital stay on the antifungal resistance of Candida strains isolated

from critically ill surgical patients. Mycopathologia 2011;171(2):85-91.

Rieger CT, Ostermann H, Kolb HJ, Fiegl M, Huppmann S,

Morgenstern N, et al. A clinical cohort trial of antifungal combination

therapy: Efficacy and toxicity in haematological cancer patients. Ann

Hematol 2008;87(11):915-22.

Panackal AA, Parisini E, Proschan M. Salvage combination antifungal

therapy for acute invasive Aspergillosis may improve outcomes: A

systematic review and meta-analysis. Int J Infect Dis 2014;28:80-94.

Trumic E, Pranjic N, Begic L, Becic F, Asceric M. Idiosyncratic adverse

reactions of most frequent drug combinations long term use among

hospitalized patients with polypharmacy. Med Arch 2012;66(4):243-8.

Published

01-03-2016

How to Cite

Islahudin, F., and L. A. Yip. “ANTIFUNGAL UTILIZATION AND OUTCOME EVALUATION IN A TERTIARY HOSPITAL”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 2, Mar. 2016, pp. 223-6, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/10454.

Issue

Section

Original Article(s)